These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34101756)

  • 1. Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.
    Koks MS; Ocak G; Suelmann BBM; Hulsbergen-Veelken CAR; Haitjema S; Vianen ME; Verhaar MC; Kaasjager KAH; Khairoun M
    PLoS One; 2021; 16(6):e0252978. PubMed ID: 34101756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
    Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors.
    Seethapathy H; Zhao S; Chute DF; Zubiri L; Oppong Y; Strohbehn I; Cortazar FB; Leaf DE; Mooradian MJ; Villani AC; Sullivan RJ; Reynolds K; Sise ME
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1692-1700. PubMed ID: 31672794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study.
    Shimamura Y; Watanabe S; Maeda T; Abe K; Ogawa Y; Takizawa H
    Clin Exp Nephrol; 2021 May; 25(5):479-487. PubMed ID: 33471239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
    Cortazar FB; Kibbelaar ZA; Glezerman IG; Abudayyeh A; Mamlouk O; Motwani SS; Murakami N; Herrmann SM; Manohar S; Shirali AC; Kitchlu A; Shirazian S; Assal A; Vijayan A; Renaghan AD; Ortiz-Melo DI; Rangarajan S; Malik AB; Hogan JJ; Dinh AR; Shin DS; Marrone KA; Mithani Z; Johnson DB; Hosseini A; Uprety D; Sharma S; Gupta S; Reynolds KL; Sise ME; Leaf DE
    J Am Soc Nephrol; 2020 Feb; 31(2):435-446. PubMed ID: 31896554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
    Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
    Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with immune check point inhibitors and acute kidney injury.
    Valentin A; Møller AKH; Palshof JA; Broberg B; Gravesen E; Svane IM; Hansen D
    Acta Oncol; 2023 Feb; 62(2):121-125. PubMed ID: 36755491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence.
    Xie W; Xiao S; Li X; Huang J; Li G; Zhang Z
    Eur J Intern Med; 2023 Sep; 115():88-95. PubMed ID: 37263805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study.
    Lumlertgul N; Vassallo P; Tydeman F; Lewis N; Hobill A; Weerapolchai K; Nordin NZ; Seylanova N; Martin L; Cennamo A; Wang Y; Rigg A; Shaunak N; Ostermann M
    Eur J Cancer; 2023 Sep; 191():112967. PubMed ID: 37499561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
    Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
    Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.
    Zhou P; Liu B; Shen N; Fan X; Lu S; Kong Z; Gao Y; Lv Z; Wang R
    Ren Fail; 2024 Dec; 46(1):2326186. PubMed ID: 38466161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
    Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single and combination immunotherapy with chemotherapy and the risk of AKI in patients with solid cancer.
    de Brito GA; Junior APN; Silva MBE; Bettim BB; Pereira BJ
    Clin Exp Nephrol; 2024 Apr; 28(4):273-281. PubMed ID: 37995062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study.
    Zhu J; Ding X; Zhang J; Chen B; You X; Chen X; Chen T
    BMC Cancer; 2024 Jun; 24(1):756. PubMed ID: 38914959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Proton Pump Inhibitor Use and Immune Checkpoint Inhibitor-Mediated Acute Kidney Injury: A Meta-Analysis and a Review of Related Outcomes.
    Mohan A; Krisanapan P; Tangpanithandee S; Thongprayoon C; Kanduri SR; Cheungpasitporn W; Herrmann SM
    Am J Nephrol; 2024; 55(4):439-449. PubMed ID: 38471492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
    Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
    Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoints inhibitors and its link to acute kidney injury and renal prognosis.
    Kanbay M; Yildiz AB; Siriopol D; Vehbi S; Hasbal NB; Kesgin YE; Celayir M; Selcukbiricik F; Covic A; Perazella MA
    Int Urol Nephrol; 2023 Apr; 55(4):1025-1032. PubMed ID: 36282399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors.
    García-Carro C; Bolufer M; Bury R; Castañeda Z; Muñoz E; Felip E; Lorente D; Carreras MJ; Gabaldon A; Agraz I; Serón D; Soler MJ
    Nephrol Dial Transplant; 2022 Apr; 37(5):887-894. PubMed ID: 33547795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.